Last edition
News about "Sasha Koniev"
GSK Gains Exclusive Rights to Syndivia's Prostate Cancer ADC
GSK has obtained exclusive rights from Syndivia for a preclinical Antibody-Drug Conjugate (ADC) targeting metastatic Castration-Resistant Prostate Cancer (mCRPC), addressing an urgent need for novel therapies. The agreement expands GSK’s oncology pipeline with a potential best-in-class ADC designed to deliver enhanced anti-tumour activity.
Sasha Koniev | 27/10/2025 | By Dineshwori | 202
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members